Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Expression of Yes-associated protein modulates Survivin expression in primary liver malignancies.

Bai H, Gayyed MF, Lam-Himlin DM, Klein AP, Nayar SK, Xu Y, Khan M, Argani P, Pan D, Anders RA.

Hum Pathol. 2012 Sep;43(9):1376-85. doi: 10.1016/j.humpath.2011.12.001. Epub 2012 Mar 19.

2.

Inducible liver-specific overexpression of gankyrin in zebrafish results in spontaneous intrahepatic cholangiocarcinoma and hepatocellular carcinoma formation.

Huang SJ, Cheng CL, Chen JR, Gong HY, Liu W, Wu JL.

Biochem Biophys Res Commun. 2017 Aug 26;490(3):1052-1058. doi: 10.1016/j.bbrc.2017.06.164. Epub 2017 Jun 28.

PMID:
28668389
3.
4.

Liver stem cells: implications for hepatocarcinogenesis.

Alison MR.

Stem Cell Rev. 2005;1(3):253-60. Review.

PMID:
17142862
5.

Survivin in survival of hepatocellular carcinoma.

Su C.

Cancer Lett. 2016 Sep 1;379(2):184-90. doi: 10.1016/j.canlet.2015.06.016. Epub 2015 Jun 25. Review.

PMID:
26118774
6.

Deregulation of Hippo kinase signalling in human hepatic malignancies.

Li H, Wolfe A, Septer S, Edwards G, Zhong X, Abdulkarim AB, Ranganathan S, Apte U.

Liver Int. 2012 Jan;32(1):38-47. doi: 10.1111/j.1478-3231.2011.02646.x. Epub 2011 Oct 20.

7.

Mutation inactivation of Nijmegen breakage syndrome gene (NBS1) in hepatocellular carcinoma and intrahepatic cholangiocarcinoma.

Wang Y, Hong Y, Li M, Long J, Zhao YP, Zhang JX, Li Q, You H, Tong WM, Jia JD, Huang J.

PLoS One. 2013 Dec 13;8(12):e82426. doi: 10.1371/journal.pone.0082426. eCollection 2013.

8.

The oncogenic role of NS5A of hepatitis C virus is mediated by up-regulation of survivin gene expression in the hepatocellular cell through p53 and NF-κB pathways.

Jiang YF, He B, Li NP, Ma J, Gong GZ, Zhang M.

Cell Biol Int. 2011 Dec;35(12):1225-32. doi: 10.1042/CBI20110102.

PMID:
21612579
9.

H3K4 dimethylation in hepatocellular carcinoma is rare compared with other hepatobiliary and gastrointestinal carcinomas and correlates with expression of the methylase Ash2 and the demethylase LSD1.

Magerl C, Ellinger J, Braunschweig T, Kremmer E, Koch LK, Höller T, Büttner R, Lüscher B, Gütgemann I.

Hum Pathol. 2010 Feb;41(2):181-9. doi: 10.1016/j.humpath.2009.08.007. Epub 2009 Nov 6.

PMID:
19896696
10.

Secretin receptors in the human liver: expression in biliary tract and cholangiocarcinoma, but not in hepatocytes or hepatocellular carcinoma.

Körner M, Hayes GM, Rehmann R, Zimmermann A, Scholz A, Wiedenmann B, Miller LJ, Reubi JC.

J Hepatol. 2006 Dec;45(6):825-35. Epub 2006 Jul 28.

PMID:
16935383
11.

Hepatitis B virus X protein modulates oncogene Yes-associated protein by CREB to promote growth of hepatoma cells.

Zhang T, Zhang J, You X, Liu Q, Du Y, Gao Y, Shan C, Kong G, Wang Y, Yang X, Ye L, Zhang X.

Hepatology. 2012 Dec;56(6):2051-9. doi: 10.1002/hep.25899. Epub 2012 Nov 13.

PMID:
22707013
12.

α-Fetoprotein-producing gastric carcinoma and combined hepatocellular and cholangiocarcinoma show similar morphology but different histogenesis with respect to SALL4 expression.

Ikeda H, Sato Y, Yoneda N, Harada K, Sasaki M, Kitamura S, Sudo Y, Ooi A, Nakanuma Y.

Hum Pathol. 2012 Nov;43(11):1955-63. doi: 10.1016/j.humpath.2011.11.022. Epub 2012 Apr 17.

PMID:
22516245
13.

Co-activation of PIK3CA and Yap promotes development of hepatocellular and cholangiocellular tumors in mouse and human liver.

Li X, Tao J, Cigliano A, Sini M, Calderaro J, Azoulay D, Wang C, Liu Y, Jiang L, Evert K, Demartis MI, Ribback S, Utpatel K, Dombrowski F, Evert M, Calvisi DF, Chen X.

Oncotarget. 2015 Apr 30;6(12):10102-15.

14.

Survivin-mediated cancer cell migration through GRP78 and epithelial-mesenchymal transition (EMT) marker expression in Mahlavu cells.

Tai CJ, Chin-Sheng H, Kuo LJ, Wei PL, Lu HH, Chen HA, Liu TZ, Liu JJ, Liu DZ, Ho YS, Wu CH, Chang YJ.

Ann Surg Oncol. 2012 Jan;19(1):336-43. doi: 10.1245/s10434-011-1692-5. Epub 2011 Apr 23.

PMID:
21516372
15.

Frequent alteration of the Yin Yang 1/Raf-1 kinase inhibitory protein ratio in hepatocellular carcinoma.

Notarbartolo M, Giannitrapani L, Vivona N, Poma P, Labbozzetta M, Florena AM, Porcasi R, Muggeo VM, Sandonato L, Cervello M, Montalto G, D'Alessandro N.

OMICS. 2011 May;15(5):267-72. doi: 10.1089/omi.2010.0096. Epub 2011 Feb 19.

PMID:
21332389
16.

High levels of BCL-2 messenger RNA detected by in situ hybridization in human hepatocellular and cholangiocellular carcinomas.

Fiorentino M, D'Errico A, Altimari A, Barozzi C, Grigioni WF.

Diagn Mol Pathol. 1999 Dec;8(4):189-94.

PMID:
10617275
17.

The expression of Survivin and NF-κB associated with prognostically worse clinicopathologic variables in hepatocellular carcinoma.

Jin Y, Chen J, Feng Z, Fan W, Wang Y, Li J, Tong D.

Tumour Biol. 2014 Oct;35(10):9905-10. doi: 10.1007/s13277-014-2279-0. Epub 2014 Jul 5.

PMID:
24996542
18.

The utility of keratin 903 as a new prognostic marker in mass-forming-type intrahepatic cholangiocarcinoma.

Aishima S, Asayama Y, Taguchi K, Sugimachi K, Shirabe K, Shimada M, Sugimachi K, Tsuneyoshi M.

Mod Pathol. 2002 Nov;15(11):1181-90.

19.

Survivin expression in hepatocellular carcinoma: correlation with proliferation, prognostic parameters, and outcome.

Fields AC, Cotsonis G, Sexton D, Santoianni R, Cohen C.

Mod Pathol. 2004 Nov;17(11):1378-85.

20.

Inducible nitric oxide synthase and survivin messenger RNA expression in hepatocellular carcinoma.

Ikeguchi M, Ueta T, Yamane Y, Hirooka Y, Kaibara N.

Clin Cancer Res. 2002 Oct;8(10):3131-6.

Supplemental Content

Support Center